|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
|
Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f... |
|
|
Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting
In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care.
Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide i... |
|
|
Updates in the Diagnosis and Management of Chronic Lymphocytic Leukemia: Strategies for Addressing Disparities in Patient Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Advances in chronic lymphocytic leukemia (CLL) testing and therapy have redefined the standard of care in recent years, prompting updates to current guideline recommendations. At the same time, findings from ongoing clinical trials continue to inform treatment options and de... |
|
|
Clinical Consultations™ Integrating Modern Antipsychotic Medications into the Management of Patients with Schizophrenia
Activity Overview
Schizophrenia is a common psychiatric disorder with a significant long-term disease burden considered greater than that associated with any other mental illness. It is one of the most stigmatized psychiatric illnesses. Use of atypical antipsychotic medications is effective for many patients, yet relapse is common and often due to medication nonadherence. Main among the myriad of reasons underlying nonadherence are adverse effects that include weight gain and sedation and pat... |
|
|
Advances in Bispecific Antibodies for B-Cell Non-Hodgkin Lymphoma: Rapid Response From New Orleans
Non-Hodgkin lymphoma (NHL) is the most common type of lymphoma, of which B-cell lymphomas (eg, diffuse large B-cell lymphoma [DLBCL], follicular lymphoma [FL], and mantle cell lymphoma [MCL]) are some of the most common subtypes. Historically, first-line treatment is most commonly rituximab plus chemotherapy with or without radiation therapy. With treatment advances, more patients are eligible for newer first-line treatment options such as immunotherapy, targeted therapy, and CAR T-cell therap... |
|
|
Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma
ACTIVITY DESCRIPTION
Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with ... |
|
|
On Topic Virtual Roundtable: “BTK Battle” " Experts Compare and Contrast the Latest Data of BTK Inhibitors for the Treatment of Hematologic Malignancies
Program Overview
This online roundtable discussion will focus on the use of BTK in patients with CLL/SLL, lymphoma, and other hematologic malignancies, as well as expert guidance in the selection and sequencing of this class of agents safely and effectively.
Target Audience
The target audience for this activity is community and academic medical oncologists, pulmonologists, allied health professionals, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hema... |
|
|
A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion f... |
|
|
Ace the Case: Multiple Myeloma Presentation in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma
Program Overview
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts treating patients with multiple myeloma.
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and ot... |
|
|
Neuromyelitis Optica Spectrum Disorder: Management Updates and Challenging Clinical Cases
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. NMOSD is often misdiagnosed in the early stages, but the integration of newer diagnostic criteria may assist in an earlier and more accurate differential diagnosis. Until recently, treatment options for NMOSD have been limited―but several approved biologic thera... |
|
|
Neuromyelitis Optica Spectrum Disorder: Management Updates and Challenging Clinical Cases
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. NMOSD is often misdiagnosed in the early stages, but the integration of newer diagnostic criteria may assist in an earlier and more accurate differential diagnosis. Until recently, treatment options for NMOSD have been limited―but several approved biologic thera... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
|
The Role of the Clinical Pharmacist in the Management of Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is characterized by monoclonal proliferation of malignant plasma cells that accumulate within the bone marrow. The incidence of MM has increased in recent years, in part due to the revised definition of symptomatic MM from the International Myeloma Working Group in 2014. The National Cancer Institute estimated a total of 34,470 new cases in 2022, with 12,640 deaths. Despite significant advancements ... |
|
|
PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team
Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati... |
|
|
Codependency: Causes, Consequences and Cures
In this course, the author offers in-depth and in-person strategies for therapists to use in working with clients who present with the characteristic behavior patterns of codependency. Clients are usually unaware of the underlying codependency that is often responsible for the symptoms they’re suffering. Starting with emphasis on the delicate process of building a caring therapeutic relationship with these clients, the author guides readers through the early shame-inducing parenting styles t... |
|